Long classified as a subset of common liver cancer, FLC should be considered its own unique disease. Now researchers are testing a combination drug therapy that targets FLC tumors.

In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options ...

A new study found that getting a glass of milk's worth of calcium per day, whether or not it comes from dairy, can lower ...

Information on tumor mutational status was limited before the development of NGS because traditional Sanger sequencing and ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its CEO, Steve ...

Individualized treatments for cancer show great promise, and three KC-area providers are dialing up their offerings.

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug ...

Traditionally, the dose of a cancer drug chosen ... a drug target and provide tests to distinguish rapidly between responders and nonresponders to a drug. Several molecular imaging probes are ...

The Perlmutter Cancer Center at New York City-based NYU Langone Health recently launched its new Center for Molecular Oncology, naming Shridar Ganesan, MD, PhD, as director. The center will manage, ...

T CDx is a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients. xT CDx ...

Cancer is a disease of the genome, according to Dr. Elli Papaemmanuil, computational oncologist at MSK. By looking at the ...